2a97

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 4: Line 4:
==Overview==
==Overview==
-
The seven serologically distinct Clostridium botulinum neurotoxins (BoNTs, A-G) are zinc endopeptidases which block the neurotransmitter release by, cleaving one of the three proteins of the soluble, N-ethylmaleimide-sensitive-factor attachment protein receptor complex, (SNARE complex) essential for the fusion of vesicles containing, neurotransmitters with target membranes. These metallopeptidases exhibit, unique specificity for the substrates and peptide bonds they cleave., Development of countermeasures and therapeutics for BoNTs is a priority, because of their extreme toxicity and potential misuse as biowarfare, agents. Though they share sequence homology and structural similarity, the, structural information on each one of them is required to understand the, mechanism of action of all of them because of their specificity., Unraveling the mechanism will help in the ultimate goal of developing, inhibitors as antibotulinum drugs for the toxins. Here, we report the, high-resolution structure of active BoNT/F catalytic domain in two crystal, forms. The structure was exploited for modeling the substrate binding and, identifying the S1' subsite and the putative exosites which are different, from BoNT/A or BoNT/B. The orientation of docking of the substrate at the, active site is consistent with the experimental BoNT/A-LC:SNAP-25 peptide, model and our proposed model for BoNT/E-LC:SNAP-25.
+
The seven serologically distinct Clostridium botulinum neurotoxins (BoNTs A-G) are zinc endopeptidases which block the neurotransmitter release by cleaving one of the three proteins of the soluble N-ethylmaleimide-sensitive-factor attachment protein receptor complex (SNARE complex) essential for the fusion of vesicles containing neurotransmitters with target membranes. These metallopeptidases exhibit unique specificity for the substrates and peptide bonds they cleave. Development of countermeasures and therapeutics for BoNTs is a priority because of their extreme toxicity and potential misuse as biowarfare agents. Though they share sequence homology and structural similarity, the structural information on each one of them is required to understand the mechanism of action of all of them because of their specificity. Unraveling the mechanism will help in the ultimate goal of developing inhibitors as antibotulinum drugs for the toxins. Here, we report the high-resolution structure of active BoNT/F catalytic domain in two crystal forms. The structure was exploited for modeling the substrate binding and identifying the S1' subsite and the putative exosites which are different from BoNT/A or BoNT/B. The orientation of docking of the substrate at the active site is consistent with the experimental BoNT/A-LC:SNAP-25 peptide model and our proposed model for BoNT/E-LC:SNAP-25.
==About this Structure==
==About this Structure==
Line 21: Line 21:
[[Category: clostridium botulinum neurotoxin serotype f; light chain; catalytic domain; x-ray; crystal structure; zinc endopeptidase]]
[[Category: clostridium botulinum neurotoxin serotype f; light chain; catalytic domain; x-ray; crystal structure; zinc endopeptidase]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Feb 3 10:22:49 2008''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:25:06 2008''

Revision as of 14:25, 21 February 2008


2a97, resolution 1.80Å

Drag the structure with the mouse to rotate

Crystal structure of catalytic domain of Clostridium botulinum neurotoxin serotype F

Overview

The seven serologically distinct Clostridium botulinum neurotoxins (BoNTs A-G) are zinc endopeptidases which block the neurotransmitter release by cleaving one of the three proteins of the soluble N-ethylmaleimide-sensitive-factor attachment protein receptor complex (SNARE complex) essential for the fusion of vesicles containing neurotransmitters with target membranes. These metallopeptidases exhibit unique specificity for the substrates and peptide bonds they cleave. Development of countermeasures and therapeutics for BoNTs is a priority because of their extreme toxicity and potential misuse as biowarfare agents. Though they share sequence homology and structural similarity, the structural information on each one of them is required to understand the mechanism of action of all of them because of their specificity. Unraveling the mechanism will help in the ultimate goal of developing inhibitors as antibotulinum drugs for the toxins. Here, we report the high-resolution structure of active BoNT/F catalytic domain in two crystal forms. The structure was exploited for modeling the substrate binding and identifying the S1' subsite and the putative exosites which are different from BoNT/A or BoNT/B. The orientation of docking of the substrate at the active site is consistent with the experimental BoNT/A-LC:SNAP-25 peptide model and our proposed model for BoNT/E-LC:SNAP-25.

About this Structure

2A97 is a Single protein structure of sequence from Clostridium botulinum with and as ligands. Active as Bontoxilysin, with EC number 3.4.24.69 Known structural/functional Sites: , , , , , , and . Full crystallographic information is available from OCA.

Reference

Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design., Agarwal R, Binz T, Swaminathan S, Biochemistry. 2005 Sep 6;44(35):11758-65. PMID:16128577

Page seeded by OCA on Thu Feb 21 16:25:06 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools